Eli Lilly and Co (NYSE:LLY) Cyramza (ramucirumab) showed improved overall survival rate compared to chemotherapy alone in patients suffering from second-line non-small cell lung cancer (:NSCLC) in a global phase III study (:REVEL). The company announced detailed results from the REVEL study (n=1253) at the American Society of Clinical Oncology Annual Meeting. Eli Lilly and Co (NYSE:LLY) net profit margin is 17.40% and weekly performance is -0.38%. On last trading day company shares ended up $59.63. Analysts mean target price for the company is $60.88. Eli Lilly and Co (NYSE:LLY) distance from 50-day simple moving average (SMA50) is 1.32%.
BNP Paribas reiterated their neutral rating on shares of AstraZeneca plc (NYSE:AZN) in a research report sent to investors on Thursday morning. AstraZeneca plc (ADR) (NYSE:AZN) shares advanced 0.86% in last trading session and ended the day on $72.86. AZN Gross Margin is 79.80% and its return on assets is 3.70%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly performance is 8.84%.
VIVUS, Inc. (NASDAQ:VVUS) shares moved up 3.54% in last trading session and was closed at $5.27, while trading in range of $5.08 – $5.43. VIVUS, Inc. (NASDAQ:VVUS) year to date (YTD) performance is -41.96%.
Arena Pharmaceuticals (NASDAQ:ARNA) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 46,073,021 shares, a decline of 9.0% from the April 30th total of 50,611,732 shares, Stock Ratings Network reports. Approximately 21.2% of the company’s shares are sold short. Based on an average trading volume of 7,053,411 shares, the days-to-cover ratio is presently 6.5 days. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended the last trading day at $6.00. Company weekly volatility is calculated as 3.29% and price to cash ratio as 5.14. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -2.44%.
Jefferies Group reiterated their positive rating on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note released on Monday morning. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares ended the day on $6.69. ARIA return on assets is -66.50%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -17.71%.